Stock Events

Stock Events

Homology Medicines 

0
61
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q1 2026
Q2 2026
Next
-0.58
-0.48
-0.38
-0.28
Expected EPS
-0.275264
Actual EPS
N/A

Financials

53.85%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
45.8MRevenue
24.66MNet Income

Analyst Ratings

28.83Average Price Target
The highest estimate is 50.08.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 35H.MU. It's not an investment recommendation.
NVIDIA
7
NVDA
Intel
7
INTC
Realty Income
6
O
Alphabet
6
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is a leader in the development of gene-based therapies using CRISPR/Cas9 technology, directly competing with Homology's gene editing platform.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the gene editing space using CRISPR technology, similar to Homology Medicines, targeting genetic diseases.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another key player in CRISPR-based gene editing, competing in the same space as Homology Medicines for genetic disorder treatments.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, competing in the genetic disease treatment market.
Regenxbio
RGNX
Mkt Cap637.69M
REGENXBIO is a biotechnology company focusing on the development, commercialization of gene therapies, directly competing with Homology's gene therapy approach.
Pfizer
PFE
Mkt Cap159.36B
Pfizer, through its acquisition of Bamboo Therapeutics and other initiatives, has entered the gene therapy space, making it a competitor in the broader market that Homology Medicines operates in.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, with its acquisition of Kite Pharma and focus on cell therapies, competes in the advanced therapy medicinal products space, including gene therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals, through its collaboration with CRISPR Therapeutics and focus on treating genetic diseases, competes in the same therapeutic areas as Homology Medicines.

About

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Show more...
CEO
Jodie Pope Morrison
Employees
22
Country
United States
ISIN
US4380831077

Listings

LSE
GB
0T6G.LSE
STU
DE
DB0.STU
XNAS
US
QTTB
MU
DE
35H.MU

0 Comments

Share your thoughts

FAQ

What is Homology Medicines stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Homology Medicines stocks are traded under the ticker 35H.MU.
When is the next Homology Medicines earnings date?▼
Homology Medicines is going to release the next earnings report on November 05, 2026.
What were Homology Medicines earnings last quarter?▼
35H.MU earnings for the last quarter are -0.38 EUR per share, whereas the estimation was -0.4 EUR resulting in a +4.34% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Homology Medicines revenue for the last year?▼
Homology Medicines revenue for the last year amounts to 45.8M EUR.
What is Homology Medicines net income for the last year?▼
35H.MU net income for the last year is 24.66M EUR.
How many employees does Homology Medicines have?▼
As of September 04, 2026, the company has 22 employees.
In which sector is Homology Medicines located?▼
Homology Medicines operates in the Health & Wellness sector.
When did Homology Medicines complete a stock split?▼
The last stock split for Homology Medicines was on March 26, 2024 with a ratio of 1:18.
Where is Homology Medicines headquartered?▼
Homology Medicines is headquartered in WALTHAM, United States.